Zimmer Biomet Holdings, Inc. (ZBH)
USD 105.86
(-2.04%)
USD 105.86
(-2.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9 Billion USD | -0.34% |
| 2022 | 9.03 Billion USD | -16.23% |
| 2021 | 10.79 Billion USD | -11.69% |
| 2020 | 12.21 Billion USD | -0.23% |
| 2019 | 12.24 Billion USD | -4.71% |
| 2018 | 12.85 Billion USD | -12.19% |
| 2017 | 14.63 Billion USD | -13.54% |
| 2016 | 16.92 Billion USD | -3.8% |
| 2015 | 17.59 Billion USD | 465.37% |
| 2014 | 3.11 Billion USD | -5.13% |
| 2013 | 3.28 Billion USD | 4.27% |
| 2012 | 3.14 Billion USD | 4.85% |
| 2011 | 3 Billion USD | 34.74% |
| 2010 | 2.22 Billion USD | 3.73% |
| 2009 | 2.14 Billion USD | 35.44% |
| 2008 | 1.58 Billion USD | 34.18% |
| 2007 | 1.18 Billion USD | 12.38% |
| 2006 | 1.05 Billion USD | 1.39% |
| 2005 | 1.03 Billion USD | -40.62% |
| 2004 | 1.74 Billion USD | -12.95% |
| 2003 | 2 Billion USD | 307.17% |
| 2002 | 492.6 Million USD | -26.07% |
| 2001 | 666.3 Million USD | 98.07% |
| 2000 | 336.4 Million USD | 56.47% |
| 1999 | 215 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 8.84 Billion USD | -1.8% |
| 2024 Q3 | 9.33 Billion USD | 6.46% |
| 2024 Q2 | 8.77 Billion USD | -0.86% |
| 2023 FY | 9 Billion USD | -0.34% |
| 2023 Q1 | 9.08 Billion USD | 0.52% |
| 2023 Q2 | 8.91 Billion USD | -1.87% |
| 2023 Q3 | 8.69 Billion USD | -2.43% |
| 2023 Q4 | 9 Billion USD | 3.56% |
| 2022 Q4 | 9.03 Billion USD | -0.48% |
| 2022 Q1 | 9.59 Billion USD | -11.06% |
| 2022 Q2 | 9.32 Billion USD | -2.79% |
| 2022 Q3 | 9.08 Billion USD | -2.64% |
| 2022 FY | 9.03 Billion USD | -16.23% |
| 2021 Q3 | 11.29 Billion USD | -2.97% |
| 2021 Q1 | 11.57 Billion USD | -5.25% |
| 2021 Q2 | 11.63 Billion USD | 0.55% |
| 2021 FY | 10.79 Billion USD | -11.69% |
| 2021 Q4 | 10.79 Billion USD | -4.47% |
| 2020 Q4 | 12.21 Billion USD | 0.58% |
| 2020 Q1 | 13.63 Billion USD | 11.3% |
| 2020 FY | 12.21 Billion USD | -0.23% |
| 2020 Q2 | 12 Billion USD | -11.93% |
| 2020 Q3 | 12.14 Billion USD | 1.2% |
| 2019 FY | 12.24 Billion USD | -4.71% |
| 2019 Q2 | 12.54 Billion USD | -1.62% |
| 2019 Q3 | 12.22 Billion USD | -2.5% |
| 2019 Q4 | 12.24 Billion USD | 0.13% |
| 2019 Q1 | 12.74 Billion USD | -0.79% |
| 2018 Q3 | 13.15 Billion USD | -2.14% |
| 2018 Q4 | 12.85 Billion USD | -2.34% |
| 2018 FY | 12.85 Billion USD | -12.19% |
| 2018 Q2 | 13.44 Billion USD | -11.43% |
| 2018 Q1 | 15.18 Billion USD | 3.74% |
| 2017 Q3 | 15.96 Billion USD | -1.53% |
| 2017 Q2 | 16.21 Billion USD | -4.92% |
| 2017 Q1 | 17.05 Billion USD | 0.75% |
| 2017 FY | 14.63 Billion USD | -13.54% |
| 2017 Q4 | 14.63 Billion USD | -8.35% |
| 2016 Q3 | 17.29 Billion USD | 4.75% |
| 2016 Q1 | 16.63 Billion USD | -4.0% |
| 2016 Q4 | 16.92 Billion USD | -2.11% |
| 2016 FY | 16.92 Billion USD | -3.8% |
| 2016 Q2 | 16.5 Billion USD | -0.78% |
| 2015 Q3 | 16.69 Billion USD | -2.24% |
| 2015 Q2 | 17.07 Billion USD | 61.01% |
| 2015 Q1 | 10.6 Billion USD | 240.83% |
| 2015 FY | 17.59 Billion USD | 465.37% |
| 2015 Q4 | 17.33 Billion USD | 3.8% |
| 2014 Q1 | 3.14 Billion USD | -4.21% |
| 2014 Q4 | 3.11 Billion USD | -0.56% |
| 2014 Q2 | 3.18 Billion USD | 1.39% |
| 2014 FY | 3.11 Billion USD | -5.13% |
| 2014 Q3 | 3.12 Billion USD | -1.77% |
| 2013 Q1 | 3.03 Billion USD | -3.62% |
| 2013 FY | 3.28 Billion USD | 4.27% |
| 2013 Q4 | 3.28 Billion USD | 1.93% |
| 2013 Q3 | 3.21 Billion USD | 0.33% |
| 2013 Q2 | 3.2 Billion USD | 5.79% |
| 2012 Q2 | 2.9 Billion USD | -1.28% |
| 2012 Q1 | 2.94 Billion USD | -1.95% |
| 2012 FY | 3.14 Billion USD | 4.85% |
| 2012 Q4 | 3.14 Billion USD | 6.53% |
| 2012 Q3 | 2.95 Billion USD | 1.68% |
| 2011 Q2 | 2.23 Billion USD | -0.89% |
| 2011 Q3 | 2.59 Billion USD | 15.97% |
| 2011 Q4 | 3 Billion USD | 15.84% |
| 2011 FY | 3 Billion USD | 34.74% |
| 2011 Q1 | 2.25 Billion USD | 1.11% |
| 2010 Q4 | 2.22 Billion USD | 2.15% |
| 2010 Q2 | 2.09 Billion USD | -0.73% |
| 2010 FY | 2.22 Billion USD | 3.73% |
| 2010 Q1 | 2.1 Billion USD | -1.8% |
| 2010 Q3 | 2.18 Billion USD | 4.25% |
| 2009 FY | 2.14 Billion USD | 35.44% |
| 2009 Q4 | 2.14 Billion USD | 28.6% |
| 2009 Q3 | 1.66 Billion USD | 0.78% |
| 2009 Q2 | 1.65 Billion USD | -1.19% |
| 2009 Q1 | 1.67 Billion USD | 5.77% |
| 2008 FY | 1.58 Billion USD | 34.18% |
| 2008 Q1 | 1.2 Billion USD | 2.4% |
| 2008 Q2 | 1.43 Billion USD | 18.55% |
| 2008 Q3 | 1.45 Billion USD | 1.39% |
| 2008 Q4 | 1.58 Billion USD | 9.02% |
| 2007 Q1 | 978.9 Million USD | -6.88% |
| 2007 Q4 | 1.18 Billion USD | 6.28% |
| 2007 Q3 | 1.11 Billion USD | 7.4% |
| 2007 Q2 | 1.03 Billion USD | 5.72% |
| 2007 FY | 1.18 Billion USD | 12.38% |
| 2006 FY | 1.05 Billion USD | 1.39% |
| 2006 Q1 | 990.6 Million USD | -4.46% |
| 2006 Q2 | 1.06 Billion USD | 7.52% |
| 2006 Q3 | 1.1 Billion USD | 3.46% |
| 2006 Q4 | 1.05 Billion USD | -4.6% |
| 2005 Q1 | 1.43 Billion USD | -17.73% |
| 2005 FY | 1.03 Billion USD | -40.62% |
| 2005 Q2 | 1.24 Billion USD | -13.31% |
| 2005 Q3 | 1.11 Billion USD | -10.59% |
| 2005 Q4 | 1.03 Billion USD | -6.86% |
| 2004 Q1 | 1.87 Billion USD | -6.76% |
| 2004 Q4 | 1.74 Billion USD | 3.36% |
| 2004 Q3 | 1.68 Billion USD | -6.79% |
| 2004 Q2 | 1.81 Billion USD | -3.1% |
| 2004 FY | 1.74 Billion USD | -12.95% |
| 2003 FY | 2 Billion USD | 307.17% |
| 2003 Q1 | 436.1 Million USD | -11.47% |
| 2003 Q2 | 494.6 Million USD | 13.41% |
| 2003 Q3 | 499.3 Million USD | 0.95% |
| 2003 Q4 | 2 Billion USD | 301.7% |
| 2002 Q3 | 577 Million USD | -11.2% |
| 2002 Q1 | 656.3 Million USD | -1.5% |
| 2002 Q2 | 649.8 Million USD | -0.99% |
| 2002 FY | 492.6 Million USD | -26.07% |
| 2002 Q4 | 492.6 Million USD | -14.63% |
| 2001 Q3 | 714.6 Million USD | 79.5% |
| 2001 Q2 | 398.1 Million USD | -2.19% |
| 2001 FY | 666.3 Million USD | 98.07% |
| 2001 Q1 | 407 Million USD | 21.13% |
| 2001 Q4 | 666.3 Million USD | -6.76% |
| 2000 Q4 | 336 Million USD | 0.0% |
| 2000 FY | 336.4 Million USD | 56.47% |
| 1999 FY | 215 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott Laboratories | 34.38 Billion USD | 73.802% |
| Allurion Technologies Inc. | 142.19 Million USD | -6235.277% |
| Artivion, Inc. | 510.61 Million USD | -1664.277% |
| Avanos Medical, Inc. | 456.1 Million USD | -1875.159% |
| Butterfly Network, Inc. | 84.22 Million USD | -10596.501% |
| Butterfly Network, Inc. | 84.22 Million USD | -10596.501% |
| Bio-Rad Laboratories, Inc. | 3.55 Billion USD | -153.2% |
| Boston Scientific Corporation | 15.6 Billion USD | 42.274% |
| Perspective Therapeutics, Inc. | 3.44 Million USD | -261097.449% |
| CONMED Corporation | 1.46 Billion USD | -514.593% |
| Edwards Lifesciences Corporation | 2.64 Billion USD | -240.748% |
| Paragon 28, Inc. | 162.95 Million USD | -5428.234% |
| Glaukos Corporation | 478.64 Million USD | -1782.114% |
| Globus Medical, Inc. | 1.08 Billion USD | -727.911% |
| Inspire Medical Systems, Inc. | 104.29 Million USD | -8537.545% |
| Integer Holdings Corporation | 1.41 Billion USD | -537.458% |
| Medtronic plc | 39.56 Billion USD | 77.228% |
| Nevro Corp. | 330.31 Million USD | -2627.339% |
| Owlet, Inc. | 73.79 Million USD | -12107.076% |
| Penumbra, Inc. | 377.36 Million USD | -2287.29% |
| Vicarious Surgical Inc. | 21.89 Million USD | -41045.01% |
| Smith & Nephew plc | 4.77 Billion USD | -88.862% |
| Sonendo, Inc. | 49.74 Million USD | -18011.216% |
| STERIS plc | 4.74 Billion USD | -89.723% |
| Stryker Corporation | 21.31 Billion USD | 57.743% |
| Vapotherm, Inc. | 132.95 Million USD | -6675.955% |